The field of USP1 inhibitors is rapidly evolving, and these clinical trials will provide crucial data for this novel therapeutic approach in cancer management, particularly for patients with HRD-positive tumors and those resistant to PARP inhibitors. The gene discussed is USP1; the disease is cancer.